Precision Medicine in Oncology®

Notch-targeted agents that were initially intended for the treatment of Alzheimer disease are now being examined for their possible anticancer activity.

Ashish M. Kamat, MD, from MD Anderson Cancer Center, discusses enhancing clinical trial recruitment through a novel definition of BCG therapy failure in patients with nonmuscle invasive bladder cancer.

Collaborative and standardized efforts to develop and evaluate novel drugs are necessary to ultimately provide effective long-term treatment for nonmuscle-invasive bladder cancer.

The FDA approved regorafenib for the treatment of gastrointestinal stromal tumors that cannot be removed surgically and no longer respond to other FDA-approved treatments for the disease.

William J. Gradishar, MD, from the Northwestern University Feinberg School of Medicine, describes the need to enrich the patient population in a clinical trial that is investigating a novel targeted therapy.

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma.

Leyland-Jones, MB BS, PhD, a renowned oncologist and translational scientist, has helped develop several mainstay oncologic treatments and the targeted breast cancer therapy trastuzumab.

New discoveries about tumor biology suggest to many researchers that targeted therapies, when used in appropriate early-stage patients, might significantly boost cure rates and extend lives.

Ghassan K. Abou-Alfa, MD, from Memorial Sloan-Kettering Cancer Center, discusses the promising results and future investigation of MET inhibition in hepatocellular carcinoma using cabozantinib and tivantinib.

While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific mutations more efficiently.

As therapy based on cell-signaling pathways has become a priority in cancer research, so has the concept of designing clinical trials that can better target patient populations more likely to benefit from a particular regimen.

Patients with breast cancer who do not exhibit amplifications of the HER2 gene may still have mutations of HER2 that drive the progression of their cancer, suggesting that these mutations could serve as therapeutic targets.

A new drug screening method revealed that cholesterol-reducing statin drugs used in combination with cyclin-dependent kinase inhibitors might serve as an effective treatment approach for certain types of melanoma.

Antibody-drug conjugates are a robust area of oncology exploration, with an estimated 25 ADCs under study in clinical trials, up from six less than a decade ago.

Activation of a signaling pathway involving the proto-oncogene Src is responsible for disease progression and metastasis in cancer and beta blocker drugs could be used to reduce mortality in these patients.